AUG 27·SEC EDGARLow
FOSTER JAMES C sold $10.1M of CRL
FOSTER JAMES C sold 33,561 shares of CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) at $300.00 ($10.07M total) on 2026-08-25 under a Rule 10b5-1 trading plan.
StockNYSE · US · USDHealthcare · Diagnostics & Research
$CRL
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
alphai earnings readsecond quarter 2026 · AUG 5Charles River Laboratories Announces Second-Quarter 2026 ResultsVerdict: mixedRead →
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Price · $CRLvia TradingView
AI sentiment · 7d2 articles
- Bullish
- 1
- Neutral
- 1
- Bearish
- 0
Insider · 30dAll trades →
- Buys
- — 0 txs
- Sells
- $25.7M 17 txs
Knell Michael Gunnar9× · $1.7M
10b5-1 share of filings35%
Top stories · $CRLMore →
AUG 23·simplywall.st
Is Charles River (CRL) Quietly Redefining Its Edge Through Complex Biologics and Vaccine Testing?
Charles River Laboratories (CRL) partners with Medigen to support vaccine development, highlighting its role in complex biologics testing. The collaboration aligns with CRL's strategy to focus on high-value testing. Analysts project $4.1B revenue and $461.2M earnings by 2029, though some see slower growth due to potential industry shifts.
AUG 22·simplywall.st
What Does Charles River Laboratories International (CRL) Gain From This Vaccine Collaboration?
Charles River Laboratories (CRL) and Medigen Vaccine Biologics Corp. announced a collaboration to develop a multivalent enterovirus vaccine. The partnership leverages CRL's analytics for vaccine development and regulatory readiness, expanding CRL's biologics testing services and reducing reliance on animal testing. CRL, a $13.9B life sciences company, aims to diversify into higher-margin, data-driven analytics. Investors will watch for regulatory milestones and pipeline growth.
CRL sentiment & insider activity
Over the past 7 days, alphai's AI scored 2 news stories mentioning CRL (CHARLES RIVER LABORATORIES INTERNATIONAL, INC.). Coverage has skewed bullish: 1 bullish, 1 neutral, and 0 bearish.
Recent CRL coverage spans insider activity, financial news and technology.
In the last 30 days, CRL insiders filed 17 SEC Form 4 transactions — no purchases and 17 sales ($25.7M). The most active reporter was Knell Michael Gunnar, SVP, Finance and CAO, with 9 filings. 35% of those filings were made under pre-arranged Rule 10b5-1 plans.
What's driving CRL
The insider sale may signal negative sentiment and could pressure the stock short‑term.
The deal expands Charles River's biologics and vaccine testing capabilities, potentially boosting long‑term revenue from high‑value contracts.
The deal expands CRL's biologics testing services and could drive higher-margin non‑clinical work if it leads to repeat contracts.
Curaleaf's share price rose modestly despite typical acquirer weakness, reflecting market optimism about the deal.
The gift is a routine insider transaction with negligible market impact.
alphai scores every news story that mentions CRL with an AI model for sentiment and relevance, and aggregates insider trades from CHARLES RIVER LABORATORIES INTERNATIONAL, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
News on $CRL
Score
FOSTER JAMES C sold $10.1M of CRL
FOSTER JAMES C sold 33,561 shares of CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) at $300.00 ($10.07M total) on 2026-08-25 under a Rule 10b5-1 trading plan.
1 min readIs Charles River (CRL) Quietly Redefining Its Edge Through Complex Biologics and Vaccine Testing?
Charles River Laboratories (CRL) partners with Medigen to support vaccine development, highlighting its role in complex biologics testing. The collaboration aligns with CRL's strategy to focus on high-value testing. Analysts project $4.1B revenue and $461.2M earnings by 2029, though some see slower growth due to potential industry shifts.
2 min readWhat Does Charles River Laboratories International (CRL) Gain From This Vaccine Collaboration?
Charles River Laboratories (CRL) and Medigen Vaccine Biologics Corp. announced a collaboration to develop a multivalent enterovirus vaccine. The partnership leverages CRL's analytics for vaccine development and regulatory readiness, expanding CRL's biologics testing services and reducing reliance on animal testing. CRL, a $13.9B life sciences company, aims to diversify into higher-margin, data-driven analytics. Investors will watch for regulatory milestones and pipeline growth.
2 min read
Aurora Snipes Back At Curaleaf’s Hostile Bid
Aurora Cannabis rejected Curaleaf's hostile $4 per share bid, urging shareholders to take no action. Curaleaf claims its offer represents a 45% premium over Aurora's 30-day average share price. Aurora's shares rose 34% to $3.89, while Curaleaf's OTC shares gained 6% to $9.80. Aurora's board formed a special committee to review the offer, which expires on December 1.
2 min readCharles River (NYSE: CRL) CEO makes 528-share gift of common stock
Charles River Laboratories (CRL) CEO Birgit Girshick gifted 528 shares of common stock on 2026-08-19, leaving her with 35,485 direct and 43,803 indirect shares via a revocable trust. The gift was reported at $0.00 per share, with no Rule 10b5-1 trading plan involved.
1 min readParisotto Shannon M sold $600K of CRL
Parisotto Shannon M (CEVP, Disc & Safety Assessment) sold 2,039 shares of CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) at $294.12 ($0.60M total) on 2026-08-19 under a Rule 10b5-1 trading plan.
1 min readAndrews Nancy C sold $163K of CRL
Andrews Nancy C sold 573 shares of CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) at $285.24 ($0.16M total) on 2026-08-18.
1 min read
Charles River Laboratories and Medigen Vaccine Biologics Corp Collaborate to Advance New Vaccine Development Programs Through Next Generation Sequencing
Charles River Laboratories (CRL) and Medigen Vaccine Biologics (MVC) collaborate to develop MVC's next-generation multivalent enterovirus vaccine. CRL will use its Next-Generation Sequencing (NGS) technology to support CMC activities. MVC's ENVACGEN® vaccine is approved in Taiwan and Vietnam. The partnership aims to accelerate vaccine development and meet global regulatory standards.
2 min readBiotech Stocks At 52-Week Highs - AMLX +63% With Phase 3 Data, VOGX +25%, OBIO +19%, ATRC, CRL
Several biotech stocks hit 52-week highs on August 18, 2026. Amylyx (AMLX) surged 63% to $35.39 after positive Phase 3 data and a $350M share offering. Vogenx (VOGX) rose 25% to $20.01 post-IPO. AtriCure (ATRC) reached $46.33 with 12.8% revenue growth. Charles River (CRL) hit $289.60 despite a 2.7% revenue dip. Orchestra BioMed (OBIO) climbed 19% to $5.77 with FDA breakthrough designations.
3 min read
Birgit Girshick maps out Charles River's post-divestiture future: re-accelerating growth and a lighter portfolio
Charles River Laboratories (NYSE: CRL) CEO Birgit Girshick, in an interview, said the company will re-accelerate growth with a sharper focus on regulated safety assessment, expanded client data sharing, and non-animal testing. She discussed CRL’s two 2024 divestitures, its “Pathway to Purpose” strategy, and a deeper data-sharing partnership with Eli Lilly (NYSE: LLY).
4 min read